Immatics N.V
Research Immatics N.V (IMTX) on Bullrun: market cap USD 1.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMTX
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.02B
- Financial periodQ2 2026
- RevenueEUR 9.14M
- Net income-EUR 62.49M
- Free cash flow-EUR 61.33M
- Gross margin-582.6%
Valuation Snapshot
latest market cap is USD 1.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 48.27M | -EUR 196.45M | -EUR 183.43M | -280.9% | -1.61 | EUR 345.92M | EUR 15.64M | EUR 484.10M |
| FY2024 | EUR 155.84M | EUR 15.22M | -EUR 174.51M | 5.0% | 0.14 | EUR 236.75M | EUR 16.20M | EUR 574.84M |
| FY2023 | EUR 54.00M | -EUR 94.65M | -EUR 12.73M | -119.8% | -1.18 | EUR 218.47M | EUR 15.40M | EUR 217.62M |
| FY2022 | EUR 172.83M | EUR 27.70M | EUR 93.92M | 38.2% | 0.55 | EUR 148.52M | EUR 14.56M | EUR 203.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.02B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.41B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 864.22M | 59.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 891.43M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 663.94M | 8.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 845.74M | n/a | n/a | n/a |
About Immatics N.V
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immatics N.V's market cap?
Immatics N.V's market capitalization is USD 1.02B.
What does Immatics N.V do?
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.